{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:18Z","timestamp":1790882358817,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010071"],"award-info":[{"award-number":["2022A1515010071"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012321"],"award-info":[{"award-number":["2021A1515012321"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515020075"],"award-info":[{"award-number":["2021B1515020075"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102952","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:48:48Z","timestamp":1787255328000},"page":"102952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dynamic body mass index trajectories are associated with survival outcomes in advanced Hepatocellular Carcinoma treated with immunotherapy"],"prefix":"10.1016","volume":"72","author":[{"given":"Shuifang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0167-1029","authenticated-orcid":false,"given":"Mingcong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziniu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2026.102952_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.tranon.2026.102952_bib0002","first-page":"221","article-title":"[Cancer incidence and mortality in China, 2022]","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"10360","key":"10.1016\/j.tranon.2026.102952_bib0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tranon.2026.102952_bib0004","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.tranon.2026.102952_bib0005","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102952_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35799","article-title":"Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types","volume":"131","author":"Mastrolonardo","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102952_bib0007","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s12672-025-02970-w","article-title":"Identification of biomarkers associated with exhausted CD8+ T cells in the tumor microenvironment of intrahepatic cholangiocarcinoma based on mendelian randomization and bioinformatics analysis","volume":"16","author":"Feng","year":"2025","journal-title":"Discover Oncol."},{"key":"10.1016\/j.tranon.2026.102952_bib0008","article-title":"Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study","volume":"74","author":"Yu","year":"2025","journal-title":"Cancer Immunol. Immunther."},{"issue":"4","key":"10.1016\/j.tranon.2026.102952_bib0009","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clbc.2026.02.006","article-title":"Impact of post-neoadjuvant chemotherapy biomarker changes on long-term oncological outcomes in non-pCR breast cancer","volume":"26","author":"Lu","year":"2026","journal-title":"Clin. Breast. Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2026.102952_bib0010","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2013viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.tranon.2026.102952_bib0011","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.102952_bib0012","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6603932","article-title":"Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies","volume":"97","author":"Larsson","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102952_bib0013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41574-019-0161-2","article-title":"The 'obesity paradox' in action with cancer immunotherapy","volume":"15","author":"Lysaght","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J. ImmunOther Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102952_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with Immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMa Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102952_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102952_bib0017","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00262-020-02680-y","article-title":"Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"69","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Immunther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J. ImmunOther Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.102952_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes. Endocrinol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102952_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0021","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JS9.0000000000001860","article-title":"Dynamic changes of serum \u03b1-fetoprotein predict the prognosis of bevacizumab plus immunotherapy in hepatocellular carcinoma","volume":"111","author":"Yang","year":"2025","journal-title":"Int. J. Surg."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-clinpsy-081122-012416","article-title":"Recent advances in group-based trajectory modeling for clinical research","volume":"20","author":"Nagin","year":"2024","journal-title":"Ann. Rev. Clin. Psychol."},{"key":"10.1016\/j.tranon.2026.102952_bib0023","article-title":"Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy","volume":"9","author":"Chen","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cmet.2019.10.013","article-title":"STAT3 Activation-induced fatty acid oxidation in CD8(+) T effector cells is critical for obesity-promoted breast tumor growth","volume":"31","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.tranon.2026.102952_bib0025","article-title":"Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.102952_bib0027","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.tranon.2026.102952_bib0028","doi-asserted-by":"crossref","first-page":"19471","DOI":"10.1002\/cam4.6549","article-title":"Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"12","author":"Murata","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40364-023-00535-z","article-title":"Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102952_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaoncol.2022.5409","article-title":"Association of body mass index with the safety profile of Nivolumab with or without Ipilimumab","volume":"9","author":"McQuade","year":"2023","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.tranon.2026.102952_bib0031","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/JHC.S453262","article-title":"The influence of visceral adiposity on overall survival: exploring \"obesity paradox\" among hepatocellular carcinoma patients who receiving immunotherapy","volume":"Volume 11","author":"Zhou","year":"2024","journal-title":"J. HepatoCell Carcinoma"},{"issue":"6","key":"10.1016\/j.tranon.2026.102952_bib0032","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/jcsm.13615","article-title":"Longitudinal body composition identifies hepatocellular carcinoma with cachexia following combined immunotherapy and target therapy (CHANCE2213)","volume":"15","author":"Jin","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:35:34Z","timestamp":1790739334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S1936523326002883"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102952","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic body mass index trajectories are associated with survival outcomes in advanced Hepatocellular Carcinoma treated with immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102952"}}